Continuum Advisory’s T2 Biosystems, Inc TTOO Stock Holding History

Continuum Advisory’s Portfolio TTOO Stock Details TTOO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-205	Closed	-$4.52K	–	498
2023 Q3	$4.52K	Buy	+205	New	+$5.35K	﹤0.01%	449
2022 Q4	–	Sell	-10	Closed	-$6K	–	442
2022 Q3	$6K	Hold	10	–	–	﹤0.01%	404
2022 Q2	$8K	Hold	10	–	–	﹤0.01%	402
2022 Q1	$19K	Hold	10	–	–	﹤0.01%	375
2021 Q4	$26K	Hold	10	–	–	0.01%	298
2021 Q3	$47K	Hold	10	–	–	0.01%	285
2021 Q2	$61K	Hold	10	–	–	0.02%	267
2021 Q1	$66K	Hold	10	–	–	0.03%	168
2020 Q4	$62K	Hold	10	–	–	0.03%	150
2020 Q3	$66K	Hold	10	–	–	0.04%	144
2020 Q2	$76K	Buy	10 +2	+25%	+$8.49K	0.05%	139
2020 Q1	$24K	Buy	8 +6	+300%	+$24.9K	0.02%	134
2019 Q4	$12K	Hold	2	–	–	0.01%	138
2019 Q3	$24K	Hold	2	–	–	0.02%	125
2019 Q2	$17K	Hold	2	–	–	0.01%	131
2019 Q1	$26K	Buy	+2	New	+$34K	0.02%	123

Other funds holding TTOO

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Continuum Advisory's TTOO Position: Q4 2023 in Review

Continuum Advisory sold out of T2 Biosystems, Inc (TTOO) in Q4 2023, closing a stake of 205 shares — an estimated $4.52K sold.

Continuum Advisory first reported a position in TTOO in Q1 2019 and held it in 16 quarters. The position peaked at $76K in Q2 2020. 21 funds tracked by Wall St. Rank hold TTOO as of Q4 2023.

Continuum Advisory reported no remaining T2 Biosystems, Inc position as of Q4 2023 after selling out during the quarter.
Continuum Advisory sold 205 T2 Biosystems, Inc shares in Q4 2023, an estimated $4.52K.
Continuum Advisory first reported a position in T2 Biosystems, Inc in Q1 2019 and held it in 16 quarters.
Continuum Advisory's T2 Biosystems, Inc position peaked at $76K in Q2 2020.
21 funds tracked by Wall St. Rank held T2 Biosystems, Inc as of Q4 2023.

Based on Continuum Advisory's 13F filing for Q4 2023, filed 14 Feb 2024.